Home>>Signaling Pathways>> Immunology/Inflammation>> Pulmonary Diseases>>Salbutamol (hydrochloride)

Salbutamol (hydrochloride) (Synonyms: Levalbuterol, (-)-Salbutamol, (R)-Salbutamol)

Catalog No.GC44868

Levalbuterol ((R)-Albuterol) hydrochloride is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol.

Products are for research use only. Not for human use. We do not sell to patients.

Salbutamol (hydrochloride) Chemical Structure

Cas No.: 50293-90-8

Size Price Stock Qty
5mg
$67.00
In stock
10mg
$127.00
In stock
25mg
$302.00
In stock
50mg
$502.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Salbutamol is an agonist of the β2-adrenergic receptor (β2-AR; Kd = 759 nM in a radioligand binding assay using CHO cells expressing the human receptor). It is selective for β2-ARs over β1- and β3-ARs (Kds = 46.8 and 21.9 μM, respectively). Salbutamol (25-50 μg/kg, i.v.) reduces acetylcholine-induced bronchospasm in anesthetized guinea pigs. It also reduces response of bronchial muscle to efferent vagal stimulation in anesthetized cats and dogs when administered at doses ranging from 1 to 2.5 and 10 to 20 μg/kg, respectively. Nebulized salbutamol reduces transpulmonary pressure in recurrent airway obstruction-affected horses (EC50 = 39.7 μg). Formulations containing salbutamol have been used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Reviews

Review for Salbutamol (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Salbutamol (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.